A better target for B-cell lymphomas: From a library of MAG antagonists to nanomolar CD22 ligands

Oct 25, 2011

Patients suffering from B-cell lymphomas can be treated with antibodies directed against the B-lymphocyte antigen CD20.

This therapy is not a cure, however, and new treatments that kill B-cells through different mechanisms are required, especially for patients with indolent lymphoid malignancies. An alternative clinical target for B-cell is CD22, a B-cell-specific member of the sialic acid binding Ig-like lectin (Siglec) family that recognizes α2,6-linked sialylated glycans as ligands. When it was demonstrated that B-cell activation can be down-regulated with sialosides, an intensive search for low-molecular-weight high-affinity was initiated.

A collaborative research effort led by Beat Ernst and colleagues at the University of Basel in Switzerland has identified selective and high-affinity CD22 antagonists, and their results are reported in ChemMedChem.

Using surface plasmon resonance, the team screened an existing library of antagonists (which were initially designed for another member of the Siglec family) for binding affinity toward CD22. The initial hit was then optimized to yield a series of CD22 antagonists with nanomolar binding affinity. Ernst's research group will next examine the potential application of these CD22 in cell depletion therapy.

Explore further: Classical enzymatic theory revised by including water motions

More information: Beat Ernst, From a Library of MAG Antagonists to Nanomolar CD22 Ligands, ChemMedChem, Permalink to the article: dx.doi.org/10.1002/cmdc.201100407

Related Stories

Targeted Tumor Therapy: When Antagonists Do the Better Job

Oct 20, 2006

Targeted tumor therapy lobs toxic payloads directly into tumors to destroy cancer cells while leaving normal cells unharmed. In the case of radiotherapy, these missiles, which should unerringly home in on the target and make ...

Recommended for you

Molecules that came in handy for first life on Earth

Nov 24, 2014

For the first time, chemists have successfully produced amino acid-like molecules that all have the same 'handedness', from simple building blocks and in a single test tube. Could this be how life started. ...

Jumping hurdles in the RNA world

Nov 21, 2014

Astrobiologists have shown that the formation of RNA from prebiotic reactions may not be as problematic as scientists once thought.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.